Surgical treatment and dilemmas in the treatment of basal cell carcinomas with intracranial propagation
Abstract
Background/Aim. Basal cell carcinoma (BCC) is one of the most common malignant skin tumors on the head in 90% of cases and is characterized by a high local infiltrating potential and destructive growth. The aim of this study was to show the characteristics of a correlation between pathohistological types of basal cell carcinoma and the size of this lesion, aggressiveness and infiltration of basal cell carcinoma, and its effect on the course of the therapy. Methods. We analyzed 27 patients operated on for BCC that affected the scalp and the bone. We described and considered the clinical characteristics (size, depth of invasion), duration and speed of intracranial propagation and then made comparison with the type of BCC. We described the extent of surgical treatment and the width of excision to determine the best course of the treatment. The patients went through examinations during the next three years. Results. According to the histopathological type the most common tumors were: infiltrative (60.2%), noduloinfiltrative (37.2%), and morpheaform (2.6%). Tumors were clinically manifested as ulcerative lesions, ulcus rodens and ulcus terebrans. Tumor diameters ranged from 2 to 25 cm. The depth of intracranial propagation depended on the histological type and tumor size. Most relapses (35%) occurred with morpheaform type of BCC. In 17 of the cases, BCC affected the bone without intracranial propagation. In 10 of the cases, basalioma infiltrated intracranial space – in 8 of the cases it infiltrated the dura and in 6 of the cases the brain parenchyma, of which in two of them, the superior sagittal sinus was affected and had to be surgically tied off. Conclusion. The aggressiveness and infiltration of basal cell carcinoma into the brain parenchyma is directly linked to the histological type and the size of the tumor. The larger the basalioma or if histopathological findings confirm morpheaform type of basalioma the larger surrounding healthy tissue, sometimes more than 3 cm in diameter, needs to be removed. In cases of these tumors postoperative radiotherapy is recommended.
References
Yenidunya MO. Surgical treatment of auricular malignancies when the anterior or posterior skin is intact. J Craniofac Surg 2013; 24(2): 350−3.
Braun-Falco O, Plewig G, Wolff HH, Winkeimann RK. Malignant epithelial tumors. In: Braun FO, Plewig G, Wolff HH, Winkeimann RK, editors. Dermatology. Berlin: Springer-Verlag; 1991. p. 1018−35.
Wade TR, Ackerman AB. The many faces of basal-cell carcino-ma. J Dermatol Surg Oncol 1978; 4(1): 23−8.
Marshall V. Premalignant and malignant skin tumours in im-munosuppressed patients. Transplantation 1974; 17(3): 272−5.
Araújo JL, Aguiar GB, Prado AU, Mayrink D, Saade N, Veiga JC. Malignant chondroid syringoma with central nervous system involvement. J Craniofac Surg 2012; 23(2): 514−5.
Rončević R, Aleksić V, Stojičić M, Jovanović M, Rončević D. Invasive, aggresive basal cell carcinoma: Carcinoma basocellulare tere-brans. Eur J Plast Surg 2006; 23: 379−84.
Vulović D, Stepić N, Pavlović A, Milićević S, Piscević B. Reconstruc-tion of the columella and the tip of the nose with an island-shaped forehead flap. Vojnosanit Pregl 2011; 68(3): 277−80. (Serbian)
Beatty ME, Habal MB. De novo cutaneous neoplasm: Biologic behavior in an immunosuppressed patient. Plast Reconstr Surg 1980; 66(4): 623−7.
Epstein E. How accurate is the visual assessment of basal car-cinoma margins. Br J Dermatol 1973; 89(1): 37−43.
Longobardi G, Diana G, Poddi V, Pagano I. Follicular cyst of the jaw developing into a keratocyst in a patient with unrecognized Gorlin-Goltz syndrome. J Craniofac Surg 2010; 21(3): 833−6.
Burg G, Hirsch RD, Konz B, Braun-Falco O. Histographic surgery: Accuracy of visual assessment of the margins of basal-cell epi-thelioma. J Dermatol Surg 1975; 1(3): 21−4.
Deo SV, Hazarika S, Shukla NK, Kumar S, Kar M, Samaiya A. Surgical management of skin cancers: Experience from a re-gional cancer centre in North India. Indian J. Cancer 2005; 42(3): 145−50.
Pennington BE, Leffell DJ. Mohs micrographic surgery: Estab-lished uses and emerging trends. Oncology (Willston Park) 2005; 19(9): 1165−71; discussion 1171−2, 1175.
Bojanović M, Zivković-Marinkov E, Veselinović D, Bojanović A, Vucković I. Malignant tumors of auricula and periauricular area. Vojnosanit Pregl 2009; 66(8): 611−6. (Serbian)
Hutcheson AC, Fisher AH, Lang PG. Basal cell carcinomas with unusual histologic patterns. J Am Acad Dermatol 2005; 53(5): 833−7.
McCutcheon B, White K, Kotwall C, Germolic D, Rebolloso Y, Hamann MS, et al. A preliminary study of imiquimod treatment in variants of basal cell carcinoma. Am Surg 2005; 71(8): 662−5.
Asilian A, Tamizifar B. Aggressive and neglected basal cell car-cinoma. Dermatol Surg 2005; 31(11 Pt 1): 1468−71.
Steve M, Paranque AR, Barthélémy I, Bui P. Management of a ba-socellular carcinoma of the cheek. Rev Stomatol Chir Maxillo-fac 2008; 109(1): 56−60.
Anwar U, Ghazal AS, Ahmad M, Sharpe DT. Horrifying basal cell carcinoma forearm lesion leading to shoulder disarticula-tion. Plast Reconstr Surg 2006; 117(1): 6e−9e.
Eisner JM, Russell M. Cartilage hair hypoplasia and multiple basal cell carcinomas 2006; 54(2 Suppl): S8−10.
Ríos-Buceta L. Management of basal cell carcinomas with positive margins. Actas Dermosifiliogr 2007; 98(10): 679−87. (Spanish)
Su SY, Giorlando F, Ek EW, Dieu T. Incomplete Excision of Basal Cell Carcinoma: A Prospective Trial. Plast Reconstr Surg 2007; 120(5): 1240−8.
Wettstein R, Erba P, Farhadi J, Kalbermatten DF, Arnold A, Haug M, et al. Incomplete excision of basal cell carcinoma in the subunits of the nose. Scand J Plast Reconstr Surg Hand Surg 2008; 42(2): 92−5.
Gargiulo M, Papa A, Capasso P, Moio M, Cubicciotti E, Parascandolo S. Electrochemotherapy for non-melanoma head and neck cancers: clinical outcomes in 25 patients. Ann Surg 2012; 255(6): 1158−64.